What dosing considerations should we keep in mind for liraglutide based on the results of the LEADER trial? And what are the implications for insulin-GLP-1 RA combination therapy?

What dosing considerations should we keep in mind for liraglutide based on the results of the LEADER trial? And what are the implications for insulin-GLP-1 RA combination therapy?

What dosing considerations should we keep in mind for liraglutide based on the results of the LEADER trial? And what are the implications for insulin-GLP-1 RA combination therapy?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Ralph DeFronzo, MD

Ralph DeFronzo, MD

Professor of Medicine
Chief of the Diabetes Division
The University of Texas Health Science Center at San Antonio
San Antonio, Texas